A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma (Q44703733)

5 December 2017

title

A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma (English)

1 reference

5 December 2017

main subject

phase II clinical trial

0 references

1 reference

11

Everett E Vokes

1 reference

5 December 2017

10

Mark J Ratain

1 reference

5 December 2017

Nicholas J Vogelzang

1

1 reference

5 December 2017

Theodore Karrison

2

1 reference

5 December 2017

Walter M Stadler

3

1 reference

5 December 2017

Juan Garcia

4

1 reference

5 December 2017

Helene Cohn

5

1 reference

5 December 2017

John Kugler

6

1 reference

5 December 2017

Thomas Troeger

7

1 reference

5 December 2017

Leonard Giannone

8

1 reference

5 December 2017

Rose Arrieta

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

5 December 2017

1 reference

5 December 2017

volume

100

1 reference

5 December 2017

issue

1

1 reference

5 December 2017

page(s)

65-71

1 reference

Global cancer statistics in the year 2000.

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Suramin: rapid loading and weekly maintenance regimens for cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Suramin's development: what did we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Suramin binds to platelet-derived growth factor and inhibits its biological activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Suramin: here to stay!?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Mineralocorticoid insufficiency due to suramin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11867

7 January 2021

Identifiers

DOI

10.1002/CNCR.11867

1 reference

5 December 2017

1 reference